Amneal Pharmaceuticals, Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company operating through three segments: Affordable Medicines (retail generics, injectables, biosimilars), Specialty (branded pharmaceuticals), and AvKARE (distribution). The company is currently in the process of acquiring Kashiv BioSciences, LLC, a related party transaction expected to close in Q3 2026.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Net Revenue | $796,197 | $724,508 | $1,518,716 | $1,419,928 |
| Gross Profit | $334,508 | $286,253 | $654,621 | $542,144 |
| Gross Margin | 42.0% | 39.5% | 43.1% | 38.2% |
| Operating Income | $129,769 | $111,372 | $271,541 | $211,719 |
| Net Income (Attributable to Amneal) | $57,662 | $22,417 | $119,918 | $34,612 |
| Diluted EPS | $0.18 | $0.07 | $0.37 | $0.11 |
| Cash & Equivalents | $127,637 | $71,544 | Balance Sheet (June 30, 2026) | |
| Total Debt (Net) | $2,570,296 (Long-term: $2,564,335; Current: $5,961) | |||
| Operating Cash Flow (6 Mo) | $(47,987) (vs. $91,227 in 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2026 revenue increased 9.9% year-over-year, driven by new product launches in the Affordable Medicines segment and strong sales of CREXONT, BREKIYA, and UNITHROID in the Specialty segment.
- Profitability: Net income attributable to Amneal surged 157% in Q2 ($57.7M vs. $22.4M) and 246% for the six-month period. This was aided by a significantly lower effective tax rate (1.9% in Q2 2026 vs. 31.1% in Q2 2025) due to jurisdictional mix changes and the "One Big Beautiful Bill Act."
- Legal Charges: The company recorded $8.1M in legal charges in Q2 2026, primarily related to antitrust litigation and the Nationwide Opioids Settlement Agreement (cash conversion elections by states).
- Acquisition Costs: $7.6M in acquisition costs were incurred in Q2 2026 related to the Kashiv Biosciences transaction, compared to none in the prior year.
- Cash Flow: Operating cash flow turned negative ($48.0M outflow) for the six months ended June 30, 2026, compared to a $91.2M inflow in 2025. This was driven by litigation settlement payments ($35.9M), Tax Receivable Agreement (TRA) payments ($38.8M), and increased inventory/receivables.
Guidance, Outlook, and Risks
- Kashiv Acquisition: The company expects to close the acquisition of Kashiv Biosciences in Q3 2026. Consideration includes $375M cash, ~29M shares of Class A stock, and up to $350M in contingent payments. The company has borrowed $180M on its revolving credit facility since June 30 to fund this.
- India Facility Damage: Severe rain in July 2026 caused water damage to an India facility. Estimated losses (inventory, property, remediation) range from $10M to $15M, with an estimated $20M in lost pre-tax profit for the second half of 2026. No amounts were recognized in Q2 financials.
- Tariff Risks: The company is evaluating the impact of potential U.S. tariffs on pharmaceutical imports. While generic products are currently exempt, future tariffs could materially increase costs if implemented as proposed.
- Legal Contingencies: Significant exposure remains regarding the Nationwide Opioids Settlement Agreement (total cash payments up to $133.5M) and ongoing antitrust class action litigation.
- Tax Receivable Agreement (TRA): A contingent TRA liability of $129.0M exists as of June 30, 2026, which would be recorded if deferred tax assets become more-likely-than-not to be utilized.
Investor Verification Checklist
- Kashiv Closing Conditions: Verify the status of regulatory approvals and shareholder votes required to close the Kashiv acquisition in Q3 2026.
- India Facility Impact: Monitor Q3 2026 results for the actual financial impact of the water damage and production delays in India.
- Tariff Implementation: Track U.S. government announcements regarding the implementation of tariffs on generic drugs and APIs post-July 2028.
- Legal Settlements: Review updates on the antitrust litigation and the specific cash conversion elections by states under the Opioids Settlement.
- Liquidity Position: Assess the company's ability to service its debt (~$2.6B) and fund the Kashiv acquisition given the recent negative operating cash flow.